GERNA Biotech is an startup founded to redefine gene therapy with a Cas-free gene editing platform.
mission: to deliver safe, precise, and repeatable treatments for patients with severe genetic disorders.
Vision: Harness innate cellular enzymes to correct faulty genes without introducing foreign nucleases.
This is the heading
Prevent Double-Strand Breaks: lower genomic instability risk
This is the heading
Enable Re-dosing: Minimized immune response allows repeated treatments over a patient’s lifetime.
This is the heading
Expand Target Range: No reliance on PAM sequences, so we can edit broader genomic loci.
This is the heading
Preserve Safety: Long guide RNAs (30 > bases) ensure pinpoint accuracy with negligible off-target edits.
Safer Gene Editing
Precise Gene Targeting
Re-dosable Gene Therapy
Versatile Editing Platform
Safer Gene Editing
No DSBs due to Cas-free platform
GERNA’s Cas-free platform edits genes without creating double-strand breaks, making therapy inherently safer. This eliminates unpredictable DNA damage (random indels or chromosomal translocations) often caused by CRISPR nucleases. By using the cell’s own enzymes for precision repair, we avoid introducing foreign cutting proteins. The result is a gentler, controlled edit — a stark contrast to traditional Cas9/Cas12 methods that cut DNA, trigger p53-linked stress responses, and pose significant safety concerns.